Work Group Leaders

Lachmann, Nico

Lachmann, Nico, PD Dr. rer. nat.

REBIRTH Unit iPSC based Haematopoietic Regeneration Institute of Experimental Haematology, Hannover Medical School


Biosketch:

N. Lachmann (*1980), PhD, is group leader ‘Translational Hematology of Congenital Diseas-es’ in the Institute of Experimental Hematology at MHH. His research focuses on the genera-tion of patient specific induced pluripotent stem cells and the subsequent hematopoietic differ-entiation towards different mature cell subsets to gain insights into the disease pathophysiology and the development of new cell based treatment approaches. Studying the ontogeny of hematopoietic cells from pluripotent stem cells he aims to generate designer immune cell targeting different genetic and non-genetic hematopoietic disorders.

Biography / About

Date of Birth:August, 1980
Function:Junior Research Group Leader

Education:

02/2001Apprenticeship as Biologic Lab Assistant, Leibniz Research Center Borstel
08/2003A-Level
09/2006B.Sc. “Life Science”, Leibniz Universität Hannover
10/2008M.Sc. “Biomedicine” Hannover Medical School (MHH), Yale University School of Medicine
01/2012PhD “Biomedicine” MHH
06/2016Priv.Doz. “Regenerative Medicine”, MHH

Academic appointments and Research posts:

07/2013PostDoc Max-Planck-Institute for Molecular Biomedicine
Since 2013Adjunct (APL) Instructor Cincinnati Childrens Hospital Medical Center
05/2015PostDoc, MHH
Since 2015Junior Group Leader, MHH

Other professional activities:

Since 2009Initiator and founder of “Rebirth goes back to school”
Since 2015External Reviewer Scientific Journals
Since 2015External Reviewer ERC, ANR

Awards and Prizes:

2012Travel Awards: American Society for Gene and Cell Therapy, ASGCT; European Society for Gene and Cell Therapy, ESGCT; International Society for Stem Cell Research, ISSCR, German Stem Cell Network GSCN
02/2013Eva-Luise Köhler Forschungspreis für seltene Erkrankungen 2013
05/2014Top Abstract Award & Best Translational Research German Society of Hematology and Oncology (DGHO)
02/2015Klaus Betke Fellowship, 2nd Klaus Betke Symposium
03/2015Best Clinical Research Award, German Society for Pulmonology (DGP)
11/2015Fellowship for Interdisciplinary Sciences, Joachim Herz Stiftung

Major research interests:

  • Pluripotent Stem Cells
  • Hematopoiesis
  • Cell and Gene Therapy
  • Innate Immunity
  • Macrophages

Furthermore:

2009Member in the REBIRTH organizing committee for the IdeenExpo, Hannover
2012Faculty of the “Ethical University of Stem Cell Research“at MHH
2014Member of the “Research Week” at MHH and Leibniz Universität Hannover
2014Member of the Young Academy at MHH
2016Member International UniStemDay at MHH

Selected Publications:

  1. Hartmann D, Fiedler J, Sonnenschein K, Just A, Pfanne A, Zimmer K, Remke J, Foinquinos A, Butzlaff M, Schimmel K, Maegdefessel L, Hilfiker-Kleiner D, Lachmann N, Schober A, Froese N, Heineke J, Bauersachs J, Batkai S, Thum T MicroRNA-Based Therapy of GATA2-Deficient Vascular Disease. Circulation. 2016;134(24):1973-90.
  2. Mucci A, Kunkiel J, Suzuki T, Brennig S, Glage S, Kuhnel MP, Ackermann M, Happle C, Kuhn A, Schambach A, Trapnell BC, Hansen G, Moritz T, Lachmann N Murine iPSC-Derived Macrophages as a Tool for Disease Modeling of Hereditary Pulmonary Alveolar Proteinosis due to Csf2rb Deficiency. Stem Cell Reports. 2016.
  3. Ackermann M, Liebhaber S, Klusmann JH, Lachmann N. Lost in translation: pluripotent stem cell-derived hematopoiesis. EMBO Molecular Medicine. 2015;7(11):1388-402.
  4. Dreyer AK, Hoffmann D, Lachmann N, Ackermann M, Steinemann D, Timm B, Siler U, Reichenbach J, Grez M, Moritz T, Schambach A, Cathomen T TALEN-mediated functional correction of X-linked chronic granulomatous disease in patient-derived induced pluripotent stem cells. Biomaterials. 2015;69:191-200.
  5. Lachmann N, Czarnecki K, Brennig S, Phaltane R, Heise M, Heinz N, Kempf H, Dilloo D, Kaever V, Schambach A, Heuser M, Moritz T Deoxycytidine-kinase knockdown as a novel myeloprotective strategy in the context of fludarabine, cytarabine or cladribine therapy. Leukemia. 2015.
  6. Lachmann N, Ackermann M, Frenzel E, Liebhaber S, Brennig S, Happle C, Hoffmann D, Klimenkova O, Lüttge D, Buchegger T, Kühnel MP, Schambach A, Janciauskiene S, Figueiredo C, Hansen G, Skokowa J, Moritz T Large-scale hematopoietic differentiation of human induced pluripotent stem cells provides granulocytes or macrophages for cell replacement therapies. Stem Cell Reports. 2015;4(2):282-96.
  7. Muller-Kuller U, Ackermann M, Kolodziej S, Brendel C, Fritsch J, Lachmann N, Kunkel H, Lausen J, Schambach A, Moritz T, Grez M. A minimal ubiquitous chromatin opening element (UCOE) effectively prevents silencing of juxtaposed heterologous promoters by epigenetic remodeling in multipotent and pluripotent stem cells. Nucleic Acids Research. 2015;43(3):1577-92.
  8. Happle C, Lachmann N, Skuljec J, Wetzke M, Ackermann M, Brennig S, Mucci A, Jirmo AC, Groos S, Mirenska A, Hennig C, Rodt T, Bankstahl JP, Schwerk N, Moritz T, Hansen G. Pulmonary transplantation of macrophage progenitors as effective and long-lasting therapy for hereditary pulmonary alveolar proteinosis. Science Translational Medicine. 2014;6(250):250ra113.
  9. Lachmann N, Happle C, Ackermann M, Luttge D, Wetzke M, Merkert S, Ackermann M, Kensah J, Jara-Avaca M, Mucci A, Skuljec J, Dittrich AM, Pfaff N, Brennig S, Schambach A, Steinemann D, Göhring G, Cantz T, Martin U, Schwerk N, Hansen G, Moritz T Gene correction of human induced pluripotent stem cells repairs the cellular phenotype in pulmonary alveolar proteinosis. American Journal of Respiratory and Critical Care Medicine. 2014;189(2):167-82.
  10. Suzuki T, Arumugam P, Sakagami T, Lachmann N, Chalk C, Sallese A, Abe S, Trapnell C, Carey B, Moritz T, Malik P, Lutzko C, Wood RE, Trapnell BC Pulmonary macrophage transplantation therapy. Nature. 2014;514(7523):450-4


[back to listing]
test
This website uses cookies and the web analytics service Google Analytics. Click here for further information on privacy.
I agree